Published in Lupus on July 17, 2013
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10
Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med (1967) 5.63
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet (2009) 4.02
On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A (1996) 3.29
Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet (2011) 2.31
Cardiac involvement in systemic lupus erythematosus. Lupus (2005) 2.08
Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation (2005) 2.03
Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation (1996) 1.92
The heart in systemic lupus erythematosus. Br Heart J (1960) 1.64
Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum (2004) 1.35
Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology (Oxford) (2006) 1.35
Lipid rafts in T cell signalling and disease. Semin Cell Dev Biol (2007) 1.29
Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab (2008) 1.21
Accelerated atherosclerosis in patients with SLE--mechanisms and management. Nat Rev Rheumatol (2012) 1.08
High incidence of autoantibodies in Fabry disease patients. J Inherit Metab Dis (2007) 1.07
Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med (1987) 1.03
Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus (2000) 1.02
Antiphospholipid antibodies in acute coronary syndrome. Lupus (2004) 1.00
The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res (2004) 1.00
Premature atherosclerotic disease in systemic lupus erythematosus--role of inflammatory mechanisms. Autoimmun Rev (2005) 0.99
Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) (2006) 0.99
Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis (2009) 0.98
Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis (1990) 0.96
Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report. Lupus (2005) 0.96
Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. J Mol Med (Berl) (1995) 0.96
Coexistence of Fabry's disease and systemic lupus erythematosus. Clin Exp Rheumatol (1998) 0.95
[Fabry's disease associated with rheumatoid arthritis. Multisystemic crossroads]. An Med Interna (2003) 0.93
Cardiac toxicity secondary to long term treatment with chloroquine. Ann Rheum Dis (2001) 0.90
Kidney involvement in systemic lupus erythematosus and Fabry's disease. Nephron (1983) 0.89
Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol (2005) 0.89
Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides. Biochem J (2004) 0.87
Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet (2004) 0.86
Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction. J Am Soc Echocardiogr (2005) 0.84
Chloroquine cardiomyopathy with conduction disorders. Heart (1999) 0.83
Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rev Allergy Immunol (2009) 0.83
[A case of Fabry's disease associated with lupus nephritis]. Nihon Jinzo Gakkai Shi (1992) 0.83
Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking. Adv Clin Chem (2009) 0.80
Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol (2004) 0.80
Prevalence of silent amyloidosis in RA and its clinical significance. J Rheumatol (2004) 0.80
Systemic lupus erythematosis presenting as isolated congestive heart failure. J Rheumatol (1985) 0.79
Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke (2005) 0.78
[Chloroquine cardiotoxicity in long-term lupus therapy in two patients]. Ann Dermatol Venereol (2009) 0.76
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med (1993) 3.35
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum (1999) 2.99
Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med (1983) 2.96
Determinats of operant behavior in humans: some differences from animals. Q J Exp Psychol (1978) 2.83
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol (1995) 2.69
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest (1997) 2.57
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
Overexpression of petunia chalcone isomerase in tomato results in fruit containing increased levels of flavonols. Nat Biotechnol (2001) 2.47
Mutagenesis of the region between env and src of the SR-A strain of Rous sarcoma virus for the purpose of constructing helper-independent vectors. Virology (1984) 2.38
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum (2000) 2.28
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Mutation of a termination codon affects src initiation. Mol Cell Biol (1984) 2.23
Increased throughput for fragment analysis on an ABI PRISM 377 automated sequencer using a membrane comb and STRand software. Biotechniques (2001) 2.15
Mixed connective tissue disease--goodbye to all that. Br J Rheumatol (1992) 2.11
Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med (1988) 2.09
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
Differential sensitivity of distinct Chlamydia trachomatis isolates to IFN-gamma-mediated inhibition. J Immunol (1999) 2.06
Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg (2000) 2.05
N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem (1994) 2.05
Anastomotic technique and survival after right hemicolectomy for colorectal cancer. Surgeon (2004) 2.04
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2001) 1.96
Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis. Ann Rheum Dis (1989) 1.85
Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. Proc Natl Acad Sci U S A (1989) 1.84
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) (2005) 1.83
Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain (2003) 1.82
Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol (1984) 1.76
Chronic norovirus infection in pediatric hematopoietic stem cell transplant recipients: a cause of prolonged intestinal failure requiring intensive nutritional support. Pediatr Transplant (2011) 1.72
Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science (1997) 1.70
Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med (1982) 1.68
Per-arnt-sim (PAS) domain-containing protein kinase is downregulated in human islets in type 2 diabetes and regulates glucagon secretion. Diabetologia (2010) 1.67
Export of dissolved organic carbon from peatlands under elevated carbon dioxide levels. Nature (2004) 1.65
B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum (2006) 1.65
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Associates of health status in patients with systemic lupus erythematosus. J Rheumatol (1999) 1.62
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis (2007) 1.62
A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) (1999) 1.60
Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford) (2007) 1.59
Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients. J Clin Invest (1985) 1.59
The BMJs question time. BMJ (1997) 1.59
An assessment of the preregistration year experience. Br Med J (Clin Res Ed) (1986) 1.58
The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection. J Infect Dis (1999) 1.58
Mycobacterium microti: more widespread than previously thought. J Clin Microbiol (1998) 1.57
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A (1999) 1.54
Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A (1999) 1.53
Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann Rheum Dis (1987) 1.53
Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum (1984) 1.53
Molecular typing of Mycobacterium bovis isolates from Cameroon. J Clin Microbiol (2001) 1.50
Euteleost fish genomes are characterized by expansion of gene families. Genome Res (2001) 1.50
The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view. Br J Rheumatol (1995) 1.49
Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Scand J Immunol (1989) 1.49
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 1.49
Prevalence, serological features, response to treatment and outcome of critical peripheral ischaemia in a cohort of lupus patients. Rheumatology (Oxford) (2008) 1.48
Sjögren's syndrome: association with type-1 diabetes mellitus. Br J Rheumatol (1989) 1.48
Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum (1985) 1.48
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) (2002) 1.47
N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol (2000) 1.47
Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet (1988) 1.46
Rejecting family practice: why medical students switch to other specialties. Fam Med (2000) 1.46
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J Virol (1996) 1.46
Is Mycoplasma hominis a vaginal pathogen? Sex Transm Infect (2001) 1.46
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis (2004) 1.45
The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology (Oxford) (1999) 1.45
Measurements of linear dimensions on fundus photographs: comparison between photographic film and digital systems. Eye (Lond) (2003) 1.44
Thyroid autoimmunity in systemic lupus erythematosus: the clinical significance of a fluctuating course. Br J Rheumatol (1995) 1.44
Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol (2001) 1.44
Muscle changes in ankylosing spondylitis. Br J Rheumatol (1983) 1.43
Aberrant control of galactosyltransferase in peripheral B lymphocytes and Epstein-Barr virus transformed B lymphoblasts from patients with rheumatoid arthritis. J Rheumatol (1993) 1.43
Anti-DNA antibodies in the primary antiphospholipid syndrome (PAPS) Br J Rheumatol (1993) 1.42
The value of testing urine in non-gonococcal urethritis. Int J STD AIDS (2005) 1.39
The tomato polygalacturonase gene and ripening-specific expression in transgenic plants. Plant Mol Biol (1988) 1.39
Systemic lupus erythematosus--disease activity, severity, treatment and costs. J Rheumatol (1994) 1.39
A discussion of the British Society of Gastroenterology survey of emergency gastroenterology workload. Clin Med (2007) 1.39
Preoperative radiotherapy for operable rectal cancer--is a lower dose to a reduced volume acceptable? Clin Oncol (R Coll Radiol) (2006) 1.39
Muscle strength and pre-osteomalacia in vegetarian Asian women. Lancet (1982) 1.39
Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) (2003) 1.38
Educational psychology in medical learning: a randomised controlled trial of two aide memoires for the recall of causes of electromechanical dissociation. Emerg Med J (2004) 1.38
Research and training review of the use of LAS, LAT and flexible training positions. Rheumatology (Oxford) (2001) 1.38
Steps in the biosynthesis of mosquito cell membrane glycoproteins and the effects of tunicamycin. Biochim Biophys Acta (1981) 1.37
Mutants of Rous sarcoma virus with extensive deletions of the viral genome. Virology (1979) 1.37
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) (2002) 1.37
Mycobacteria and autoimmunity. Immunol Today (1988) 1.36
An immunohistological study of secondary Sjögren's syndrome. Ann Rheum Dis (1984) 1.36
Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120. J Biol Chem (1993) 1.36
Clearance of Chlamydia trachomatis from the murine genital mucosa does not require perforin-mediated cytolysis or Fas-mediated apoptosis. Infect Immun (1999) 1.35
Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (2001) 1.34
Regulation of beta-cell glucose transporter gene expression. Proc Natl Acad Sci U S A (1990) 1.34
Characterization of polymyositis infiltrates using monoclonal antibodies to human leucocyte antigens. Clin Exp Immunol (1981) 1.33
Evaluation of ELISA, RPLA, and Vero cell assays for detecting Clostridium perfringens enterotoxin in faecal specimens. J Clin Pathol (1988) 1.32
SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol (1996) 1.30
Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren's syndrome (SS), and primary SS. J Rheumatol (1998) 1.30
Reproductive health beliefs and behaviors in teens with diabetes: application of the Expanded Health Belief Model. Pediatr Diabetes (2001) 1.28
Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood (2001) 1.28
Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. J Biol Chem (1999) 1.26
The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study. Psychol Med (2008) 1.26
Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J Virol (2001) 1.26
Cytokines and systemic lupus erythematosus. Ann Rheum Dis (2000) 1.26
Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol (1997) 1.25
Haematological manifestations of systemic lupus erythematosus. Blood Rev (1993) 1.25